Inhibitors of 11bgr;-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|23|6|623-633

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.6, 2016-02, pp. : 623-633

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis

By Hartmann R.W.   Muller U.   Ehmer P.B.  

European Journal of Medicinal Chemistry, Vol. 38, Iss. 4, 2003-04 ,pp. : 363-366

Elsevier

Access to resources Recommend Favorite

Type 1 11 &bgr;-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 3, 2006-09 ,pp. : 259-269

Bentham Science Publishers

Access to resources Recommend Favorite

Variants of the CYP11B2 gene predict response to therapy with candesartan

By Ortlepp J.R.   Hanrath P.   Mevissen V.   Kiel G.   Borggrefe M.   Hoffmann R.  

European Journal of Pharmacology, Vol. 445, Iss. 1, 2002-06 ,pp. : 151-152

Elsevier

Access to resources Recommend Favorite

11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

By Fotsch Christopher   Askew Ben C   Chen Jian Jeffrey  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 3, 2005-03 ,pp. : 289-303

Informa Healthcare

Access to resources Recommend Favorite

11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents

By Webster Scott Peter   Pallin Thomas David  

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 12, 2007-12 ,pp. : 1407-1422

Informa Healthcare

Access to resources Recommend Favorite